How in the heck ado we have our Market Cap with truths like these?
Malaria: GeoVax has demonstrated in both animal models and humans that its MVA-VLP vaccines induce a
Th1-biased response with both durable functional antibodies (IgG1 and IgG3) and CD4+ and CD8+ T cell
responses—both marks of an ideal malaria vaccine.
Cancer: GeoVax has a research
collaboration with a leading expert in cancer immunotherapy at the University of Pittsburgh to help select vaccine
candidates. The Company is further collaborating with ViaMune, Inc. of Athens, Georgia, with preliminary testing
demonstrating that the MVA-VLP-MUC1 vaccine, in combination with ViaMune’s synthetic MUC1 vaccine, may
meaningfully reduce tumor burden in a transgenic (Tg) human MUC1 therapeutic mouse model. GeoVax believes
that this program has the potential to generate several vaccines against different types of cancers.
Zika: To date, GeoVax has demonstrated 100%
protection of mice vaccinated with a single-dose of the Zika vaccine and exposed to a lethal dose of ZIKV.
Background: All of GeoVax’s preventative vaccine trials
have been sponsored by the NIH, with the NIH (through the HIV Vaccine Trials Network [HVTN]), in fact, running
the Company’s trials—something that is unusual within the biotechnology space.
Each of GeoVax’s preventative
vaccine trials have been sponsored by the NIH, garnering GeoVax roughly $50 million in either research support or
in-kinds funds—presenting a very unique circumstance for GeoVax.
WE deserve 100*300M mc easy...
